Multidisciplinary Association for Psychedelic Studies

Patents are the golden eggs of the booming psychedelic space. In an industry that revolves around substances that are found in nature (such as psilocybin, ibogaine or DMT) or compounds whose patents have already expired (LSD and MDMA), new patents are the primary way in which companies can ...

The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2). A year later after publishing the results from its first Phase 3 trial...

The Drug Enforcement Administration (DEA) will face activists at its headquarters in Arlington, Virginia, reported Mary-Elizabeth Gifford and Justin Grant of Lucid News. Protestors intend to block the entrance to the building to call attention to the rights of terminally ill...

Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is...

In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic...

The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness. Attempting to secure permission to treat a gravely ill patient using MDMA (universally known as the street drug ecstasy), psychiatrist Dr. Eli Kotler initiated legal...